¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Total Cholesterol kit"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • total peripheral resistance
    ÃѸ»ÃÊÀúÇ×, Àüü¸»ÃÊÀúÇ×
  • total pulmonary resistance
    (¢¡pulmonary vascular) ÇãÆÄÇ÷°üÀúÇ×, ÆóÇ÷°üÀúÇ×
  • total transposition
    ¿ÂÀÚ¸®¹Ù²ñÁõ
  • total ventilation
    ÃÑȯ±â·®
  • total volume urine
    Ãѹ财·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • total ankylosis
    ¿ÏÀü°­Á÷(èÇîïË­òÁ)
  • total anodontia
    (¿Ï)Àü¹«Ä¡Áõ(èÇîïÙíöÍñø).
  • total anomalous pulmonary venous connection
    ÀüÆóÁ¤¸Æ¿¬°áÀÌ»ó(îïøËð¡ØæææÌ¿ì¶ßÈ).
  • total anomalous pulmonary venous connection
    ÀüÆóÁ¤¸Æ¿¬°áÀÌ»ó(îïøËð¡ØæææÌ¿ì¶ßÈ)
  • total anomalous pulmonary venous return
    Àü<ÃÑ>ÆóÁ¤¸ÆÈ¯·ùÀÌ»ó(îï<õÅ>øËð¡ Øæü½êüì¶ßÈ)
  • total aphasia
    Àü½Ç¾îÁõ(îïã÷åÞñø).
  • total aphasia
    Àü½Ç¾îÁõ(îïã÷åÞñø)
  • total bacterial count
    Ãѱռö
  • total blindness
    ¿ÏÀü¸Í(îïØî), ¿ÏÀü½Ç¸í
  • total body irradiation (TBI)
    Àü½Å ¹æ»ç¼±Á¶»ç
  • total body opacification
    Àü½Å ºÒÅõ¸íÈ­
  • total body water
    ü³»ÃѼöºÐ·®
  • total body water
    ü³»ÃѼöºÐ·®.
  • total cataract
    Àüü¹é³»Àå, ¿ÏÀü¹é³»Àå
  • total color blindness
    ¿ÏÀü»ö¸Í(îïßäØî).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TRC tanned red cell; therapeutic residential center; total renin concentration; total respiratory conduc...
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
TC/HDL total cholesterol/high density lipoproteins [ratio]
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
TAC tachykinin; terminal antrum contraction; tetracaine, adrenalin, and cocaine; time-activity curve; to...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
T.ch Total cholesterol
TC Total plasma cholesterol
TPC Total plasma cholesterol
14C 1) [3H]cholesterol and
25-OH 25-hydroxy-cholesterol
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • total inversion
    Àüü ÀÚ¸®¹Ù²Þ
  • total irradiation
    Àü½Å Á¶»ç
  • total laryngectomy
    ÈĵΠÀü ÀûÃâ¼ú
  • total lymphoid irradiation
    Àü ¸²ÇÁ Á¶»ç
  • total nephrectomy
    ½Å Àü ÀýÁ¦, ½Å Àü ÀýÁ¦¼ú
  • total nerve block
    ¿ÏÀü Àü´Þ ¸¶Ãë
  • total nodal irradiation
    Àü ¸²ÇÁÀý Á¶»ç
  • total organ duplication
    Àüü ±â°ü Áߺ¹
  • total organism
    Àü½Å ±â°ü
  • total oxidation process
    ¿ÏÀü »êÈ­¹ý
  • total parenteral alimentation
    Àü ºñ °æ±¸Àû ¿µ¾ç ¼öÁÖ
  • total pelvic exenteration
    °ñ¹Ý Àü ÀûÃâ¼ú
  • total placenta previa
    Àü ÀüÄ¡ ŹÝ
  • total plexus paralysis
    ¿ÏÀü ÃÑ ¸¶ºñ
  • total pressure
    Àü¾Ð
    Àüü ¾Ð·ÂÀ» ÇÕÇÑ °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
high blood cholesterol A condition where there is an above normal level of cholesterol in the bloodstream. A level of over 200 mg/dl is known to be a risk factor for heart disease. Less than 200 is desirable, 200 to 239 is considered borderline high, over 240 is considered high.
(27 Sep 1997)
NAD(P)+-dependent cholesterol dehydrogenase <enzyme> Oxidises the 3 beta-oh group of cholesterol to cholestenone in the presence of NADP+
Registry number: EC 1.1.1.-
Synonym: NADP+-dc-dehydrogenase, cholesterol 3-dehydrogenase
(26 Jun 1999)
i-cholesterol isomerase <enzyme> 7-hydroxy group is isomerised to position 3 on ring a to form cholesterol
Registry number: EC 5.4.99.-
(26 Jun 1999)
embolism, cholesterol An embolism of lipid debris from an ulcerated atheromatous deposit, generally from a large artery to small arterial branches. It is usually small and rarely causes infarction.
(12 Dec 1998)
ldl cholesterol Low-density lipoprotein cholesterol (the bad cholesterol).
(12 Dec 1998)
lecithin-cholesterol acyltransferase <enzyme> An enzyme that reversibly transfers an acyl residue from a lecithin to cholesterol, forming a 1-acylglycerophosphocholine (a lysolecithin) and a cholesterol ester; a deficiency of this enzyme leads to an accumulation of unesterified cholesterol in plasma resulting in anaemia, proteinuria, renal failure, and corneal opacities; LCAT is also low in individuals with fish-eye disease.
Synonym: lecithin acyltransferase.
Acronym: LCAT
(05 Mar 2000)
lecithin-cholesterol transferase A plasma enzyme that catalyses the uptake of cholesterol esters by intermediate-density lipoproteins formed by high density lipoproteins.
(05 Mar 2000)
lipoproteins, hdl cholesterol Cholesterol which is contained in or bound to high density lipoproteins (hdl). High density lipoproteins transport cholesterol from peripheral tissues to the liver thereby acting as a scavenger to prevent excess accumulation and deposition of cholesterol in blood vessels.
(12 Dec 1998)
lipoproteins, ldl cholesterol Cholesterol which is contained in or bound to low density lipoproteins (ldl). Ldl transport cholesterol to peripheral tissues and regulate de novo cholesterol synthesis at these sites. Atherosclerosis is caused by the deposit of cholesterol on the walls of blood vessels, because of high concentrations of ldl cholesterol in plasma.
(12 Dec 1998)
lipoproteins, vldl cholesterol Cholesterol which is contained in or bound to very low density lipoproteins (vldl). High concentrations of vldl cholesterol are found in type IIb and type v hyperlipoproteinaemia. The end product of vldl cholesterol catabolism is ldl (low density lipoproteins).
(12 Dec 1998)
radical mastectomy, total Breast cancer treatment involving removal of the breast, the pectoral (chest) muscles, lymph nodes (the glands ) in the armpit and associated skin and subcutaneous tissue.
(12 Dec 1998)
parenteral nutrition, home total The at-home administering of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously or by some other non-alimentary route.
(12 Dec 1998)
parenteral nutrition, total The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of tpn solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins.
(12 Dec 1998)
reversal of organs, total This condition (medically called situs inversus totalis) involves complete transposition (right to left reversal) of the thoracic and abdominal organs. The heart is not in its usual position in the left chest but is on the right. Specifically related to the heart, this is referred to as dextrocardia (literally, right-hearted). And the stomach, which is normally in the left upper abdomen, is on the right. In patients with situs inversus totalis, all of the chest and abdominal organs are reversed and appear in mirror image when examined or visualised by tests such as X-ray filming. Situs inversus totalis has been estimated to occur once in about 6-8,000 births. Situs inversus occurs in a rare abnormal condition that is present at birth (congenital) called kartagener's syndrome.
(12 Dec 1998)
communication methods, total Utilization of all available receptive and expressive modes for the purpose of achieving communication with the hearing impaired, such as gestures, postures, facial expression, types of voice, formal speech and non-speech systems, and simultaneous communication.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á